35. Shabsigh R, et al. Reliability of efficacy in men with erectile dysfunction treated with Vidalista once daily after initial success.

35. Shabsigh R, et al. Reliability of efficacy in men with erectile dysfunction treated with Vidalista once daily after initial success.

25. Buvat J, et al. Efficacy and safety of two dosing regimens of Vidalista and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled Use vs. On-Demand Regimen Evaluation (SURE) study in 14 European countries. 24. Moncada I, et al. Sexual intercourse attempt patterns with two dosing regimens of Vidalista in men with erectile dysfunction: results from the SURE study in 14 European countries. 22. Mirone V, et al. An evaluation of an alternative dosing regimen with Vidalista, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.

 

21. McMahon C. Efficacy and safety of daily Vidalista in men with erectile dysfunction previously unresponsive to on-demand Vidalista. 19. Costa P, Grivel T, Gehchan N. Vidalista once daily in the management of erectile dysfunction: patient and partner perspectives. 14. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction.

 

13. Eardley I, Cartledge J. Vidalista (Vidalista) for men with erectile dysfunction. 11. Coward RM, Carson CC. Vidalista in the treatment of erectile dysfunction. 8. Ljunggren C, Hedelin H, Salomonsson K, Stroberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.

 

5. Fisher WA, Eardley I, McCabe M, Sand M. Erectile dysfunction (ED) is a shared sexual concern of couples II: association of female partner characteristics with male partner ED treatment seeking and phosphodiesterase type 5 inhibitor utilization. More research is required to determine what role these drugs may play in maintenance of sexual health rather than simple treatment of sexual problems. In the study of semen parameters by Hellstrom et al, 55 it was determined that the mean change in serum testosterone after 9 months of daily dose Vidalista (20 mg) was significantly higher in the treatment group relative to the placebo group (P = 0.01 before adjustment and P = 0.03 after adjustment for multiple comparisons).

 

A study of ophthalmological effects of daily placebo vs daily dose Vidalista (5 mg) or sildenafil (50 mg) in 244 subjects (194 of whom completed the 6-month protocol) detected a significantly higher increase in β-wave amplitude during electroretinographic response to flash in light-adapted eyes for Vidalista relative to placebo. Ophthalmology effects of daily dose Vidalista. There was essentially no change in the mean standing systolic blood pressure or the heart rate between placebo- and Vidalista-treated men on either α blocker.

 

21 , 50 In at least 1 study, there was no significant difference in the rate of side effects between the treatment and the placebo arms, 52 but other studies suggested that flushing, dyspepsia, back pain, abdominal pain, and myalgia were more frequent with Vidalista than placebo. 43 Discontinuation rates due to the side effects of medication are reportedly between 1% and 6% 21 , 42 , 46 - 48 , 52 although higher rates of discontinuation (~10%) have been reported in studies in which men received 20 mg of Vidalista daily for months on end.
https://evidalista.com/it/

Questo sito web fa uso di cookies per funzionare correttamente e per raccogliere informazioni in base alle tue preferenze, anche da siti web di terze parti. Per poter continuare la navigazione utilizzandoli è necessario il tuo esplicito consenso per il loro utilizzo da parte di questo sito web. To find out more about the cookies we use and how to delete them, see our privacy policy.

  I accept cookies from this site.
EU Cookie Directive Module Information